Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
N/A
1(25.0%)
Phase 3
1(25.0%)
4Total
Phase 2(2)
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04337450Phase 2Active Not Recruiting

DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old

Role: collaborator

NCT05154747Phase 3Active Not Recruiting

Long-Acting Treatment in Adolescents (LATA)

Role: collaborator

NCT01411644Unknown

Pheno- & Genotyping POF (WHO III)

Role: collaborator

NCT01392911Phase 2Completed

Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB

Role: collaborator

NCT00493337Not ApplicableCompleted

A Community Pharmacist-led Intervention to Improve Adherence to Lipid-lowering Treatment

Role: collaborator

All 5 trials loaded